Analysts Set ProQR Therapeutics Price Target at $7.14

The biotech company's stock received a 'Moderate Buy' rating from research firms.

Mar. 10, 2026 at 5:38am

Got story updates? Submit your updates here. ›

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have received an average price target of $7.6667 from the eight research firms currently covering the company. The stock has a 'Moderate Buy' rating, with one sell recommendation, one hold recommendation, and six buy recommendations.

Why it matters

As a clinical-stage biotech company focused on developing RNA-based therapies for severe genetic diseases, ProQR's stock performance and analyst coverage are closely watched by investors interested in the company's pipeline and potential future growth.

The details

The analysts' average price target of $7.6667 represents a potential upside from the stock's current trading price. Zacks Research recently upgraded ProQR's rating from 'strong sell' to 'hold', while Weiss Ratings maintained a 'sell (d-)' rating on the shares.

  • The analysts' price target and ratings are based on research conducted over the last year.

The players

ProQR Therapeutics N.V.

A clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases.

Zacks Research

A research firm that recently upgraded ProQR's rating from 'strong sell' to 'hold'.

Weiss Ratings

A research firm that maintained a 'sell (d-)' rating on ProQR's shares.

Got photos? Submit your photos here. ›

The takeaway

The mixed analyst ratings and price target for ProQR Therapeutics reflect the company's position as a clinical-stage biotech with a promising pipeline, but also the inherent risks and uncertainties associated with drug development.